BioSpace News Archive

Drug Development

Novo Builds Wegovy’s Cardio Case with Much-Anticipated Data Drop

Novo Nordisk posted new data at AHA 2023 showing that its blockbuster weight loss drug could cut the risk of major cardiovascular events—including heart attack—across patient subgroups.

November 13, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Lilly Notches Second Cholesterol Win with RNA Silencer

At its highest dose level of 608 mg, lepodisiran reduced lipoprotein(a) levels by a median of 94% after 48 weeks.

November 13, 2023
·
2 min read
·
Tristan Manalac
Business

Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines

The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Atara Biotherapeutics’ Stock Plunges Following Phase II MS Trial Failure

The allogeneic T-cell immunotherapy company is now approaching penny stock territory after its multiple sclerosis drug failed to reach the primary endpoint in a mid-stage study.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial

When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.

November 13, 2023
·
2 min read
·
Tristan Manalac
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront

After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.

November 13, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial

Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.

November 13, 2023
·
1 min read
·
Tyler Patchen
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.

November 13, 2023
·
8 min read
Deals

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.

November 13, 2023
·
4 min read
Skanska renovates hospital in Paducah, Kentucky, USA, for USD 98M, about SEK 1.0 billion

Skanska has signed a contract with Bon Secours Mercy Health for renovations to the Mercy Health Lourdes Hospital Tower in Paducah, Kentucky, USA.

November 13, 2023
·
1 min read